MX2018013340A - Combinaciones de vacunas terapeuticas para el vph. - Google Patents

Combinaciones de vacunas terapeuticas para el vph.

Info

Publication number
MX2018013340A
MX2018013340A MX2018013340A MX2018013340A MX2018013340A MX 2018013340 A MX2018013340 A MX 2018013340A MX 2018013340 A MX2018013340 A MX 2018013340A MX 2018013340 A MX2018013340 A MX 2018013340A MX 2018013340 A MX2018013340 A MX 2018013340A
Authority
MX
Mexico
Prior art keywords
hpv vaccine
vaccine combinations
therapeutic hpv
therapeutic
combinations
Prior art date
Application number
MX2018013340A
Other languages
English (en)
Spanish (es)
Inventor
M Bunnik Evelien
H H V Custers Jerome
C Scheper Gerrit
Khan Selina
KALLA Markus
Weidner Katrin
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2018013340A publication Critical patent/MX2018013340A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2018013340A 2016-05-02 2017-05-01 Combinaciones de vacunas terapeuticas para el vph. MX2018013340A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330562P 2016-05-02 2016-05-02
US201762447094P 2017-01-17 2017-01-17
PCT/US2017/030338 WO2017192418A1 (en) 2016-05-02 2017-05-01 Therapeutic hpv vaccine combinations

Publications (1)

Publication Number Publication Date
MX2018013340A true MX2018013340A (es) 2019-08-21

Family

ID=59215960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013340A MX2018013340A (es) 2016-05-02 2017-05-01 Combinaciones de vacunas terapeuticas para el vph.

Country Status (12)

Country Link
US (1) US10517944B2 (https=)
EP (1) EP3452087A1 (https=)
JP (1) JP7053491B2 (https=)
CN (1) CN109922829A (https=)
AU (1) AU2017259259B2 (https=)
BR (1) BR112018072372A2 (https=)
CA (1) CA3021341A1 (https=)
IL (1) IL262731A (https=)
MX (1) MX2018013340A (https=)
SG (1) SG11201808809PA (https=)
WO (1) WO2017192418A1 (https=)
ZA (1) ZA201808121B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040440T2 (hu) * 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
JP7732977B2 (ja) 2019-09-20 2025-09-02 トランスジーン Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ
US20230114464A1 (en) 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability
EP4135757A1 (en) * 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CN114681603A (zh) * 2020-11-26 2022-07-01 怡道生物科技(苏州)有限公司 基于黑猩猩腺病毒载体的治疗性hpv疫苗、其制备方法及应用
WO2024218165A1 (en) * 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine
WO2025092908A1 (zh) * 2023-11-01 2025-05-08 仁景(苏州)生物科技有限公司 治疗HPV感染相关疾病的mRNA疫苗

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ATE519855T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
AU1152402A (en) 2000-10-04 2002-04-15 Univ Pennsylvania Highly expressible genes
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
CN102703393A (zh) 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005222776A1 (en) 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
EP1809750B1 (en) 2004-11-08 2012-03-21 ChromaGenics B.V. Selection of host cells expressing protein at high levels
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
DK1996238T3 (da) 2006-02-28 2016-08-01 Vaxart Inc Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
JP5474767B2 (ja) 2007-05-15 2014-04-16 トランジェーヌ、ソシエテ、アノニム 多重遺伝子発現のためのベクター
DE102008010954A1 (de) 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
US9828414B2 (en) 2012-10-28 2017-11-28 Bavarian Nordic A/S Pr13.5 promoter for robust T-cell and antibody responses
EP3188752A2 (en) * 2014-09-03 2017-07-12 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
HUE040440T2 (hu) * 2014-11-04 2019-03-28 Janssen Vaccines & Prevention Bv Terápiás HPV16-oltóanyagok
KR20180042295A (ko) * 2015-08-20 2018-04-25 얀센 백신스 앤드 프리벤션 비.브이. 치료용 hpv18 백신

Also Published As

Publication number Publication date
CN109922829A (zh) 2019-06-21
AU2017259259B2 (en) 2020-11-19
SG11201808809PA (en) 2018-11-29
WO2017192418A8 (en) 2019-05-23
EP3452087A1 (en) 2019-03-13
JP2019514943A (ja) 2019-06-06
BR112018072372A2 (pt) 2019-02-19
JP7053491B2 (ja) 2022-04-12
US10517944B2 (en) 2019-12-31
CA3021341A1 (en) 2017-11-09
IL262731A (en) 2018-12-31
WO2017192418A1 (en) 2017-11-09
ZA201808121B (en) 2021-05-26
AU2017259259A1 (en) 2018-11-01
US20190142933A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
MX2018013340A (es) Combinaciones de vacunas terapeuticas para el vph.
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
IL265833A (en) Novel hla hpv16 unrestricted t-cell compositions, compositions and methods for their use
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
EP3094652A4 (en) Novel vaccines against hpv and hpv-related diseases
MY181175A (en) Therapeutic hpv16 vaccines
ZA202403393B (en) Synthetic chimeric poxviruses
WO2015134368A3 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
MY191539A (en) Streptococcal vaccine
MX2015014190A (es) Construccion de adn inmunomoduladora no codificante cerrada covalentemente.
SG11202001244SA (en) Hpv vaccine
MX2017016401A (es) Composiciones inmunogenas.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
EP3104883A4 (en) Tilapia lake virus vaccines
EP3254693A4 (en) Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent
EA201892488A1 (ru) Комбинации лечебных вакцин против впч
HK40029106A (en) Hpv vaccine
MX2024007378A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
MX2018013358A (es) Vacunas para el virus del papiloma humano y metodos para su uso.